2025 marked a year of execution with broad pipeline advancement and commercial readiness activities for darovasertib, supported by a deep pipeline and cash runway into 2030 addressing multiple indications with high unmet need including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted cancers. In 2026, the company plans to advance four registrational trials, including IDE849 (DLL3 TOP1 ADC) in neuroendocrine cancer and darovasertib in uveal melanoma, a poorest prognosis oncology indication where the majority of patients have no available FDA approved therapies.
Cyborg Score Rationale
The company has approximately $1.1 billion in cash and marketable securities as of September 30, 2025, expected to fund its operating plan into 2030. Recent milestones include first-patient enrollment in Phase 1 trial of IDE034, a potentially first-in-class B7H3/PTK7 bispecific TOP1 ADC. Multiple registrational programs advance clinical and commercial momentum.
Top Insights
OptimUM-02 trial topline PFS data for darovasertib/crizotinib combination in metastatic uveal melanoma expected in Q1 2026, a key near-term catalyst.
IDE034 is the company's second proprietary TOP1 ADC, designed to be internalized only when target antigens are co-expressed on same tumor cell, enhancing selectivity and tolerability relative to monovalent antibody formats.
In 2025, the company filed four INDs resulting in nine clinical programs, demonstrating rapid pipeline advancement.
Recent milestones include Phase 1 first-patient-in for IDE034 on Feb 25, 2026, appointment of new Chief Development Officer on Feb 23, 2026, and financial results on Feb 17, 2026 showing $1.05 billion in cash with multiple advancing programs.
Named Competitors
ADC/Targeted Oncology Therapies — Leading ADC developer with multiple approved therapies
Synthetic Lethality Platforms — Metabolic synthetic lethality focused oncology company
Uveal Melanoma Therapies — Co-developing darovasertib for uveal melanoma globally
Recent Developments
(Feb 2026) First patient enrolled in Phase 1 trial of IDE034, potential first-in-class B7H3/PTK7 bispecific TOP1 ADC
(Feb 2026) New Chief Development Officer appointment and inducement stock option grants for three newly hired employees
(Jan 2026) IND clearance for IDE574 (KAT6/7 inhibitor) with Phase 1 dose escalation trial targeted for Q1 2026
(Jan 2026) Business update outlining 2026 objectives: four registrational trials advancement including IDE849 and darovasertib programs
Open the full interactive IDEAYA Biosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.